March, 2024

article thumbnail

Pharmacy Focus: Policy Edition - Overview of California's Stop Dangerous Pharmacies Act

Pharmacy Times

Ron Lanton discusses California's Stop Dangerous Pharmacies Act, which aims to address understaffed chain pharmacies and reduce medication errors by implementing new regulations around pharmacy staffing, error reporting, and unsafe working conditions.

139
139
article thumbnail

What States are Doing to Regulate Pharmacy Benefit Managers

Drug Topics

In a poster presented at the 2024 American Pharmacists Association Annual Meeting and Exposition, researchers assessed state-level regulations for PBMs.

618
618
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

As Cannabis Use Increases, Pharmacists Must Be Prepared to Counsel Patients

Pharmacy Times

As more states have legalized cannabis use—both medicinal and recreational—Sera said pharmacists’ roles in counseling will become even more important.

153
153
article thumbnail

Five Things To Know: How To Use Artificial Intelligence To Be A Better Clinical Pharmacist

IDStewardship

In this article a clinical pharmacist with experience and knowledge about using artificial intelligence describes how it can be used to be a better clinical pharmacist. Authored By: Steven Smoke, Pharm.D., BCIDP, BCPT Article Posted 18 March 2024 In healthcare’s evolving landscape, artificial intelligence (AI) promises to redefine pharmacy. AI chatbots like ChatGPT and Gemini offer not-so-subtle hints at AI’s transformative potential.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Navigating the Psychedelic Renaissance: Emerging Mental Health Therapies and the Pharmacist’s Role

Pharmacy Times

Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.

149
149
article thumbnail

After Amylyx drug failure, what’s next for ALS?

PharmaVoice

The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.

299
299

More Trending

article thumbnail

Government, Industry Leaders Address the Growing Issue of PBM Practices

Drug Topics

Health care professionals, industry leaders, and politicians gathered for a virtual roundtable to discuss the state of the PBM industry.

643
643
article thumbnail

When £17m isn’t enough: FTSE firms plead to pay bosses millions more

The Guardian - Pharmaceutical Industry

Confronted by the huge salaries on offer in the US, London boardrooms are lobbying to be allowed to make their own bosses even wealthier There was a sharp intake of breath last month when the pharmaceuticals group AstraZeneca cemented chief executive Pascal Soriot’s position as the best-paid FTSE 100 boss with a £17m pay package , up from £15.3m a year earlier.

Packaging 145
article thumbnail

Cannabinoids show promise in acute migraine clinical trial

pharmaphorum

Inhaled cannabinoids have been shown to perform better than placebo in providing pain relief for people suffering from acute migraine in a clinical trial

145
145
article thumbnail

Study: Researchers Identify 25 Air Pollutants Associated With Asthma Symptoms

Pharmacy Times

Investigators found that 1,1,1 trichloroethane; 2-nitropropane; and 2,4,6 trichlorophenol were significantly associated with asthma symptoms for 3 exposure periods.

164
164
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Who’s getting left behind in the weight loss bonanza?

PharmaVoice

As the new weight loss drugs take the world by storm, companies in other areas are battening the hatches for when slimmer patients need fewer medical interventions.

279
279
article thumbnail

How expanded methadone access helped Switzerland defuse its drug crisis

STAT

ZURICH — The lobby of this addiction clinic is unremarkable, really, except for the network of metal chutes and tubes that hug the walls as they snake downward from a pharmacy on the upper floors. Every few minutes, a new prescription comes clattering down, delivering a bottle full of powerful and effective pills used to treat opioid addiction to a waiting patient at the front desk.

145
145
article thumbnail

Independent Pharmacies Continue to Face Financial Hardships as the Clock Ticks on PBM Reform

Drug Topics

As pharmacy benefit managers gain leverage to continue driving up drug prices, local pharmacies struggle to keep up and Congress has been called to act—but it might be too late

article thumbnail

With Pfizer struggling in 2023, CEO Bourla hit with 35% pay cut to $21.6M

Fierce Pharma

Pfizer knew 2023 was going to be a challenging year of transition. But even the drugmaker was surprised by the plummeting demand for its COVID-19 products, missing badly on its 2023 guidance. | After a difficult year for Pfizer, in which its share price fell by 44%, CEO Albert Bourla’s compensation fell by 35% from $33 million in 2022 to $21.6 million in 2023.

145
145
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Google's healthcare AI ambitions: New model for personal health coaching and next steps for gen AI

Fierce Healthcare

Google is doubling down on its ambitions for healthcare AI by exploring how generative AI can help clinicians in medical decision-making, understand lab and imaging information and provide con | Google is hyper-focused on generative AI in healthcare, pushing forward research to advance gen AI capabilities that can help clinicians in medical decision-making, understand lab and imaging information and provide consumers with personalized health insights based on their wearable data.

144
144
article thumbnail

Elranatamab Maintains or Improves Symptoms and Health Status of Patients With Multiple Myeloma

Pharmacy Times

This finding was evident in both examined groups and regardless of the patients' B-cell maturation antigen-directed therapy status.

160
160
article thumbnail

An ocean of answers in a single cell — how proteomics can lead to better drugs

PharmaVoice

New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.

246
246
article thumbnail

STAT+: Steward Health Care has deal to sell doctor network to UnitedHealth

STAT

Troubled hospital operator Steward Health Care, grappling with a financial crisis that’s engulfed its eight Massachusetts hospitals, has moved to shore up its finances by striking a deal to sell its nationwide physician network to insurance giant UnitedHealth’s Optum Care unit. The proposed sale of the doctors group, called Stewardship Health, is part of Steward’s plan to bolster its national system of 33 hospitals after the Dallas-based company last year fell behind in payi

Hospitals 145
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Disparities in Digital Health Portal Use Persist Beyond the COVID-19 Pandemic

Drug Topics

Although the pandemic spurred a greater need and use of online health resources, certain demographics continue to report significantly low participation in digital health portals.

582
582
article thumbnail

South Africans take on big pharma for access to ‘miracle’ cystic fibrosis drug

The Guardian - Pharmaceutical Industry

Cheri Nel cannot afford Vertex’s Trikafta medicine, so she is suing to end ‘patent abuse’ and allow a generic version Cheri Nel has a blunt message for the multibillion-dollar pharmaceutical company Vertex: “Any person that dies from today – that’s on you.” Vertex makes a “miracle drug” called Trikafta that can transform the lives of people with cystic fibrosis.

article thumbnail

Providers 'wasted' $10.6B in 2022 overturning claims denials, survey finds

Fierce Healthcare

More than 100 provider organizations want the Centers for Medicare & Medicaid Services (CMS) to take a tougher stance on Medicare Advantage (MA) plans’ practices following an industry survey es | Providers spent nearly $20 billion in 2022 pursuing delays and denials across all payer types, yet those efforts are substantially more costly on average when dealing with private plans, hundreds of hospitals and health systems told Premier in a recent survey.

Hospitals 144
article thumbnail

FDA Approves Semaglutide for New Indication Involving Cardiovascular Disease

Pharmacy Times

Semaglutide (Wegovy; Novo Nordisk) reduces the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight when combined with the standard-of-care.

FDA 160
article thumbnail

Why a pharmacist was tapped to spearhead ‘patient excellence’ at Boehringer Ingelheim

PharmaVoice

Deborah Reardon is leading a new pillar that asks, ‘Are we looking at this from a patient lens and not from a Boehringer lens?

245
245
article thumbnail

Disparities in donor acceptance rates point to need for more equitable heart transplant care

STAT

When a patient is going through end-stage heart failure, the best treatment is to get a heart transplant. The basic steps are familiar: First a patient gets on the waiting list, and then the wait begins for the offers. In recent years, access to donor hearts has gone up thanks to a change in heart allocation policy, but there are still gender- and race-based disparities in the acceptance rate of a donor heart offer by transplant teams, according to new research published Monday in the Journal of

145
145
article thumbnail

Demographics Significantly Influence Common Customer Behavior at Community Pharmacies

Drug Topics

Researchers found various reasons for why individuals chose a specific pharmacy and how they purchase OTC medication.

article thumbnail

FDA approves first MASH drug: Madrigal's Rezdiffra breaks ground in notorious biopharma graveyard

Fierce Pharma

The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended, as the FDA has approved the first drug for the fatty liver disease. | The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended. The FDA has approved Madrigal's resmetirom under the brand name Rezdiffra as the first drug for the fatty liver disease.

FDA 139
article thumbnail

Under new management, and under the cloud of the Change hack, HIMSS24 kicks off in Orlando next week

Fierce Healthcare

One of the largest health IT conferences, HIMSS24, will kick off in Orlando on Monday as a revamped trade show following a deal with Informa Markets last fall. | One of the largest health IT conferences, HIMSS24, will kick off in Orlando on Monday as a revamped trade show following a deal with Informa Markets last fall.

143
143
article thumbnail

Balancing Health Tech Innovation With Safety: Navigating the Intersection of AI and Patient Care

Pharmacy Times

Although regulation takes time, real safety concerns for patients in the rapid development of AI technology in health care are present today.

article thumbnail

GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.

PharmaVoice

Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.

Vaccines 246
article thumbnail

STAT+: During the pandemic, were great vaccines bad business? A company-by-company review

STAT

It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people and brought the world to its knees. A key factor in taming the pandemic was the creation of effective vaccines , which have saved millions of lives. You’d think developing a successful vaccine would be an unmitigated win, from a financial perspective.

Vaccines 145
article thumbnail

Improving CVD Outcomes Through Better Recommendations, Patient Monitoring

Drug Topics

Researchers detailed the FDA’s recommendations on low-dose aspirin and pharmacists’ role in cardiovascular practice transformation programs.

549
549
article thumbnail

BioNTech hit with 'notice of default' from NIH in COVID-19 vaccine royalty dispute

Fierce Pharma

Even as Germany's BioNTech deals with ongoing declines of its revenue and share price, it's facing another serious concern: U.S. | Even as Germany's BioNTech deals with ongoing declines of its revenue and share price, it's facing another serious concern: U.S. officials are pressing the company to pay royalties linked to the commercialization of its lucrative Pfizer-partnered COVID-19 vaccine.

Vaccines 139
article thumbnail

HIMSS24: 'Fasten your seatbelts'—Hackensack Meridian CEO predicts acceleration of gen AI to help healthcare workforce

Fierce Healthcare

ORLANDO — It's almost impossible to have a conversation at HIMSS24 without the topic of artificial intelligence or generative AI coming up. | How will the conversations about AI in healthcare change by next year's HIMSS conference? Hackensack Meridian CEO Robert Garrett predicts that pilot projects underway now will roll out into practice.

141
141